7/23/2013

Astellas Pharma received federal approval for the once-daily organ rejection drug Astagraf XL. The drug is an immunosuppressant to prevent organ rejection in kidney transplant patients, and is an extended-release version of the firm's Prograf.

Full Story:
PharmaTimes (U.K.)

Related Summaries